Quantifying physiologic parameters of the gastroesophageal junction during re-operative anti-reflux surgery
Sign Up to like & getrecommendations! Published in 2022 at "Surgical Endoscopy"
DOI: 10.1007/s00464-022-09025-z
Abstract: Hiatal hernia re-approximation during index anti-reflux surgery (ARS) contributes approximately 80% of overall change in distensibility index (DI) and, potentially, compliance of the gastroesophageal (GEJ), while sphincter augmentation contributes approximately 20%. Whether this is seen… read more here.
Keywords: physiologic parameters; gej; anti reflux; index ... See more keywords
Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American College of Surgeons"
DOI: 10.1097/xcs.0000000000000251
Abstract: BACKGROUND The Memorial Sloan Kettering Cancer Center (MSK) nomogram combined both gastroesophageal junction (GEJ) and gastric cancer patients and was created in an era from patients who generally did not receive neoadjuvant chemotherapy. We sought… read more here.
Keywords: gej; memorial sloan; msk nomogram; gastric cancer ... See more keywords
Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abq6146
Abstract: Inactivation of the tumor suppressor genes tumor protein p53 (TP53) and cyclin-dependent kinase inhibitor 2A (CDKN2A) occurs early during gastroesophageal junction (GEJ) tumorigenesis. However, because of a paucity of GEJ-specific disease models, cancer-promoting consequences of… read more here.
Keywords: gej; gastroesophageal junction; tp53 cdkn2a; model ... See more keywords
Adenocarcinoma of the oesophagus: is it gastric cancer?
Sign Up to like & getrecommendations! Published in 2022 at "Gut"
DOI: 10.1136/gutjnl-2022-327096
Abstract: The incidence of gastrooesophageal junction (GEJ) cancer, comprising both oesophageal (EAC) and junctional gastric adenocarcinomas, has increased dramatically in Western countries, correlating with a decrease in noncardia gastric cancer (GC). A better understanding of the… read more here.
Keywords: cancer; gej; adenocarcinoma; stomach ... See more keywords
NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4137
Abstract: TPS4137Background: Gastric cancer remains a significant health problem in the US and globally with more than 951,600 annual cases worldwide. Moreover, the incidence of GEJ-centered adenocarcinoma i... read more here.
Keywords: nci 10066; 10066 phase; olaparib combination; study olaparib ... See more keywords
KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.723
Abstract: 723Background: The US FDA approved pembro for treating pts with 1) recurrent locally advanced or metastatic G/GEJ adenocarcinoma, whose disease has progressed on or after ≥2 prior therapies and who... read more here.
Keywords: 059 cohort; pembrolizumab pembro; cohort pembrolizumab; keynote 059 ... See more keywords
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.16
Abstract: 16 Background: Physiologically, the tight junction protein CLDN18.2 is present only in the gastric mucosa. Upon malignant transformation, CLDN18.2 epitopes are exposed on the cell surface and accessible to targeted therapy. Zolbetuximab (formerly IMAB362) is… read more here.
Keywords: gej; zolbetuximab; zolbetuximab eox; first line ... See more keywords
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.383
Abstract: 383Background: Nivo is the first immune checkpoint inhibitor (ICI) to show efficacy and tolerability in G/GEJ cancer patients refractory to or intolerant of standard chemotherapy. Although Nivo has... read more here.
Keywords: gej cancer; phase iii; iii study; study nivolumab ... See more keywords
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24054877
Abstract: Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Unfortunately, nearly half of patients experience disease recurrence despite standard treatments (neoadjuvant and/or adjuvant chemotherapy/chemoradiotherapy and surgery). In… read more here.
Keywords: gej; gej cancer; times changing; growth factor ... See more keywords